Compounds > rp 170
Page last updated: 2024-11-07

rp 170

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

RP 170: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID129146
SCHEMBL ID5050584
MeSH IDM0169212

Synonyms (15)

Synonym
1,3-propanediol, 2-((2-nitro-1h-imidazol-1-yl)methoxy)-
rp-170
rp 170
2-((2-nitro-1h-imidazol-1-yl)methoxy)-1,3-propanediol
2-[(2-nitroimidazol-1-yl)methoxy]propane-1,3-diol
1-(2-hydroxy-1-(hydroxymethyl)ethoxy)methyl-2-nitroimidazole
120398-89-2
SCHEMBL5050584
DWSFCAKOSWFTCK-UHFFFAOYSA-N
1-[2-hydroxy-1-(hydroxymethyl)ethoxy]methyl-2nitroimidazol
1-[2-hydroxy-1-(hydroxymethyl)ethoxy]methyl-2-nitroimidazol
1-[2-hydroxy-1-(hydroxymethyl)ethoxy]methyl-2-nitroimidazole
2-[(2-nitro-1h-imidazol-1-yl)methoxy]-1,3-propanediol
DTXSID90152840
PD163623

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"01) less toxic than RK-28 at this dose, as reflected in a lower increase in the brain glucose level (0."( Metabolic studies and neurotoxicity in tumors and brain of mice after hypoxic cell sensitizers.
Streffer, C; Tamulevicius, P, 1994)		0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (25.00)18.7374
1990's5 (62.50)18.2507
2000's1 (12.50)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 27.40

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index27.40 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index4.49 (4.65)
Search Engine Demand Index37.53 (26.88)
Search Engine Supply Index2.90 (0.95)

This Compound (27.40)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
antipyrine
Antipyrine: An analgesic and antipyretic that has been given by mouth and as ear drops. Antipyrine is often used in testing the effects of other drugs or diseases on drug-metabolizing enzymes in the liver. (From Martindale, The Extra Pharmacopoeia, 30th ed, p29). antipyrine : A pyrazolone derivative that is 1,2-dihydropyrazol-3-one substituted with methyl groups at N-1 and C-5 and with a phenyl group at N-2.		2.0110pyrazoloneantipyretic;
cyclooxygenase 3 inhibitor;
environmental contaminant;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic
etanidazole
Etanidazole: A nitroimidazole that sensitizes hypoxic tumor cells that are normally resistant to radiation therapy.. etanidazole : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of (2-nitro-1H-imidazol-1-yl)acetic acid with the amino group of ethanolamine. Used as a radiosensitising agent for hypoxic tumour cells.		3.3670C-nitro compound;
imidazoles;
monocarboxylic acid amide		alkylating agent;
antineoplastic agent;
prodrug;
radiosensitizing agent
iodoantipyrine
[no description available]		2.0110
azomycin
azomycin: RN given refers to parent cpd with specified locant; structure		3.4880C-nitro compound;
imidazoles		antitubercular agent
misonidazole
Misonidazole: A nitroimidazole that sensitizes normally radio-resistant hypoxic cells to radiation. It may also be directly cytotoxic to hypoxic cells and has been proposed as an antineoplastic.		2.8940
pimonidazole
pimonidazole: structure given in first source		1.9710
deoxyglucose
Deoxyglucose: 2-Deoxy-D-arabino-hexose. An antimetabolite of glucose with antiviral activity.. deoxyglucose : A deoxyhexose comprising glucose having at least one hydroxy group replaced by hydrogen.		2.0110
iodofiltic acid
iodofiltic acid: labeled with 123 I for myocardial imaging; RN given refers to unlabeled, non-isomeric cpd		2.0110
doranidazole
doranidazole: structure given in first source		1.9810
ku 2285
KU 2285: structure given in first source		2.3820
1-(4'-hydroxy-2'-butenoxy)methyl-2-nitroimidazole
1-(4'-hydroxy-2'-butenoxy)methyl-2-nitroimidazole: structure given in first source		2.3820
ConditionIndicatedRelationship StrengthStudiesTrials
Experimental Neoplasms
[description not available]		02.8940
Alloxan Diabetes
[description not available]		02.0110
Heart Disease, Ischemic
[description not available]		02.0110
Myocardial Ischemia
A disorder of cardiac function caused by insufficient blood flow to the muscle tissue of the heart. The decreased blood flow may be due to narrowing of the coronary arteries (CORONARY ARTERY DISEASE), to obstruction by a thrombus (CORONARY THROMBOSIS), or less commonly, to diffuse narrowing of arterioles and other small vessels within the heart. Severe interruption of the blood supply to the myocardial tissue may result in necrosis of cardiac muscle (MYOCARDIAL INFARCTION).		02.0110